Research programme: BIO5 Institute/Johnson and Johnson Consumer and Personal Products/Janssen Biotech
Latest Information Update: 22 Jul 2015
At a glance
- Originator BIO5 Institute; Johnson & Johnson
- Developer Johnson & Johnson
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Asthma